Augmenting autophagy to treat acute kidney injury during endotoxemia in mice

PLoS One. 2013 Jul 30;8(7):e69520. doi: 10.1371/journal.pone.0069520. Print 2013.

Abstract

Objective: To determine that 1) an age-dependent loss of inducible autophagy underlies the failure to recover from AKI in older, adult animals during endotoxemia, and 2) pharmacologic induction of autophagy, even after established endotoxemia, is of therapeutic utility in facilitating renal recovery in aged mice.

Design: Murine model of endotoxemia and cecal ligation and puncture (CLP) induced acute kidney injury (AKI).

Setting: Academic research laboratory.

Subjects: C57Bl/6 mice of 8 (young) and 45 (adult) weeks of age.

Intervention: Lipopolysaccharide (1.5 mg/kg), Temsirolimus (5 mg/kg), AICAR (100 mg/kg).

Measurements and main results: Herein we report that diminished autophagy underlies the failure to recover renal function in older adult mice utilizing a murine model of LPS-induced AKI. The administration of the mTOR inhibitor temsirolimus, even after established endotoxemia, induced autophagy and protected against the development of AKI.

Conclusions: These novel results demonstrate a role for autophagy in the context of LPS-induced AKI and support further investigation into like interventions that have potential to alter the natural history of disease.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Kidney Injury / drug therapy
  • Acute Kidney Injury / etiology*
  • Acute Kidney Injury / pathology
  • Aminoimidazole Carboxamide / administration & dosage
  • Aminoimidazole Carboxamide / analogs & derivatives
  • Aminoimidazole Carboxamide / pharmacology
  • Animals
  • Autophagy / drug effects*
  • Class III Phosphatidylinositol 3-Kinases / antagonists & inhibitors
  • Endotoxemia / chemically induced
  • Endotoxemia / complications*
  • Lipopolysaccharides / adverse effects
  • Male
  • Mice
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / pharmacology*
  • Ribonucleotides / administration & dosage
  • Ribonucleotides / pharmacology
  • Sirolimus / administration & dosage
  • Sirolimus / analogs & derivatives
  • Sirolimus / pharmacology
  • TOR Serine-Threonine Kinases / antagonists & inhibitors
  • TOR Serine-Threonine Kinases / metabolism

Substances

  • Lipopolysaccharides
  • Protein Kinase Inhibitors
  • Ribonucleotides
  • Aminoimidazole Carboxamide
  • temsirolimus
  • Class III Phosphatidylinositol 3-Kinases
  • TOR Serine-Threonine Kinases
  • AICA ribonucleotide
  • Sirolimus